Avista completes $4m facility expansion at former Microtest Labs

By Melissa Fassbender

- Last updated on GMT

Avista completes $4m facility expansion at former Microtest Labs

Related tags Capital accumulation

The expanded facility features an additional 4,200 square feet of space to enhance its microbiology, sterility testing, and microbial ID service offerings.

The contract testing, development, and manufacturing organization (CDMO) announced the finished expansion at Interphex last week in New York.

The expanded facility features an additional 4,200 square feet of space to house a new microbiology laboratory and a modular cleanroom area, which features isolator technology and an ISO 6 cleanroom for sterility testing.

(Image: Avista Pharma)
(Image: Avista Pharma)

The site, formally Microtest Labs, has “an extensive client base through historical testing services as well as expanded services since being acquired by Avista Pharma​,” Patrick Walsh, CEO of Avista Pharma, told us.

We believe that continued investments in facility renovations, equipment, and services at this facility are important to maintain best-in-class service levels,​” he added.

Walsh further explained the new service offerings were requested by clients and the facility expansion “is necessary to keep pace with our intended growth targets​.”

Additional capabilities include isolator sterility testing, which enables Avista to provide sterility testing with comprehensive evaluations and a lower risk of false positives. 

This capability complements the services that we provide and is particularly sought by manufacturers such as parenteral pharmaceutical manufacturing clients​,” Walsh added.

Facility improvements also include a new microbiology laboratory and support area with new autoclaves and glassware washers.

We continue to invest in our existing service offerings and to rapidly expand new offerings​,” Walsh explained.

In addition to the expansion at its Agawam, MA facility, Avista is currently making investments at other Avista Pharma facilities, including increased scale of API manufacturing and solid dose finished product manufacturing at its Longmont, CO facility.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us

Webinars

Headlines